Platelet Rich Plasma News and Research

RSS

Although blood mainly consists of a liquid called plasma, it also contains a number of other components including red cells, white cells, and platelets. Platelets circulate in the blood and play a crucial role in blood clotting. They also contain proteins called growth factors, which are needed to stimulate the healing of injuries.

Revised CPG on treatment of osteoarthritis of the knee addresses two key changes

The American Academy of Orthopaedic Surgeons recently released its revised clinical practice guideline on the treatment of osteoarthritis of the knee, addressing two key changes.

5 Jun 2013

Bioactive plasma-based biomaterials can accelerate tissue healing

Platelet-rich plasma derived from blood contains growth factors and other bioactive molecules that promote healing at sites of tissue injury. However, it is difficult to deliver and retain these molecules at a target site, and clinical results have proven to be mixed - until now.

16 Apr 2013

Research on sports-related concussion, sudden cardiac death to be presented at 2013 AMSSM Annual Meeting

The latest research for sports-related concussion and sudden cardiac death in athletes, in addition to a record number of sports medicine research submissions, will be presented by members of the American Medical Society for Sports Medicine at the 2013 AMSSM Annual Meeting.

2 Apr 2013

PRP treatment reduces pain in patients with chronic tennis elbow

Eighty-four percent of patients suffering from chronic tennis elbow (lateral epicondylar tendinopathy) reported significantly less pain and elbow tenderness at six months following platelet rich plasma (PRP) treatment, according to results from the largest, multi-center study, to date, on PRP and tennis elbow, presented today at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

24 Mar 2013

Platelet-rich plasma holds great promise in treating knee OA

A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis.

13 Feb 2013

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.

31 Jan 2013

HSS receives NFL grant for research into platelet-rich plasma and stem cells

Researchers at Hospital for Special Surgery have been awarded a $100,000 grant from the National Football League (NFL) Charities to research the use of platelet-rich plasma (PRP) and stem cells as treatments for tendon injury and degeneration. For years, PRP has been used to improve healing in various sports injuries, but there is little evidence of its efficacy.

12 Sep 2012

Kessler Foundation to present recent findings in spinal cord injury research at ASCIP conference

Scientists from Kessler Foundation are presenting recent findings in spinal cord injury research during Beyond Boundaries: the 2012 Conference of the Academy of Spinal Cord Injury Professionals (ASCIP).

16 Aug 2012

Link between maternal metabolic or psychological stress and obesity in offspring

A new report involving mice suggests that a relationship exists between maternal metabolic or psychological stress and the development of obesity, type 2 diabetes, and metabolic syndrome in her offspring. What's more, the report shows that if the stress cannot be reduced or eliminated, manipulating the neuropeptide Y (NPY) system in visceral fat may prevent maternal stress-induced obesity from occurring in the next generation.

1 Aug 2012

PRP therapy safe and effective method of treatment for athletes with cartilage tears

When it comes to treating cartilage tears in athletes, Platelet Rich Plasma (PRP) therapy is a safe and effective method of treatment, according to research presented today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in Baltimore.

16 Jul 2012

AOSSM to present ten research awards and seven grants during annual meeting in Baltimore

In order to recognize and encourage cutting-edge research in key areas of orthopaedic sports medicine, the American Orthopaedic Society for Sports Medicine (AOSSM) will present ten research awards and seven grants during its Annual Meeting, July 12-15 in Baltimore, MD. As a leader in orthopaedic sports medicine, AOSSM annually provides more than $350,000 to research initiatives and projects around the country.

12 Jul 2012

FDA approves Arteriocyte’s ACD-A for use with Magellan system

Arteriocyte Medical Systems, Inc. announced today approval by the U.S. Food and Drug Administration (FDA) to manufacture and distribute the Arteriocyte Medical Systems brand of Anticoagulant Citrate Dextrose Solution, USP (ACD-A) for use with its Magellan Platelet Separation System.

5 Jun 2012

Highlights of orthopaedic research studies in JBJS

Below are highlights of orthopaedic research studies appearing in the May 2, 2012 issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents.

9 May 2012

FDA grants IDE approval for Arteriocyte's Magellan MAR01 Phase I Compartment Syndrome clinical trial

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.

7 Apr 2012

Combined bioactive peptides successfully stimulate wound healing

Researchers have combined bioactive peptides to successfully stimulate wound healing. The in vitro and in vivo study, published today in PLoS ONE, demonstrates that the combination of two peptides stimulates the growth of blood vessels and promotes re-growth of tissue. Further development of these peptides could lead to a new treatment for chronic and acute wounds.

24 Feb 2012

PRP therapy shows promise against elbow injuries

As elbow injuries continue to rise, especially in pitchers, procedures to help treat and get players back in the game quickly have been difficult to come by. However, a newer treatment called platelet rich plasma (PRP) may pose hope, according to researchers presenting their findings at the American Orthopaedic Society for Sports Medicine's Specialty Day meeting in San Francisco.

13 Feb 2012

Combination of tenotomy and PRP injections can treat tendon disorders

Many athletes know the frustration of being sidelined by tendon disorders, like Achilles tendinitis and tennis elbow. In recent years, doctors have begun treating overused tendons with regenerative therapies that jump-start the body's own healing process. One technique, a tenotomy, uses repeated needlesticks to break up scar tissue in the tendon, prompting the body's own cells to begin the rebuilding process.

18 Jan 2012

Arthrex to market ThermoGenesis Res-Q 60 System technology for PRP and BMC preparation

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store human cell concentrates, said today it has entered into a five year collaboration with Arthrex, Inc., under which Arthrex will market ThermoGenesis' Res-Q 60 (Res-Q) System technology for use in the preparation of autologous Platelet Rich Plasma (PRP) and Bone Marrow Concentrate (BMC).

11 Jan 2012

Study evaluates use of leukocyte and platelet-rich fibrin biomaterial in heart patients

Cardiac patients that take anticoagulant medications and need a tooth extraction face an increased risk of bleeding that must be addressed by the treating clinician. Therefore, a protocol for heart patients is needed that will avoid significant bleeding after dental extractions without suspending anticoagulant therapy.

15 Dec 2011

BioParadox's VitaKine PCT can serve as promising therapy for heart attack patients

BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine- Platelet Cell Therapy as a promising treatment for heart attack patients.

8 Apr 2011